Li Ning Li
Directeur/Membre du Conseil chez HaploX Investment Holding Ltd.
Profil
Li Ning Li is a professional who currently holds a Non-Executive Director position at HaploX Investment Holding Ltd.
Prior to this, she worked as a Director of Operations at Grains Valley Venture Capital in 2009.
Ms. Li graduated from the University of Cardiff in 2006 with a graduate degree and from China Pharmaceutical University in 1998 with an undergraduate degree.
Postes actifs de Li Ning Li
| Sociétés | Poste | Début |
|---|---|---|
HaploX Investment Holding Ltd.
 HaploX Investment Holding Ltd. Miscellaneous Commercial ServicesCommercial Services HaploX Investment Holding Ltd. engages in the provision of genetic testing solutions with a focus on using molecular diagnostics technologies. It offers genetic testing results that enable full cycle health management for cancer and other patients as well as health screening and risk assessment for individuals, genetic testing of pathogenic microbes, and other pathogens, to research and development genetic testing primarily for biopharmaceutical companies and research institutes. The company was founded by Ming Yan Xu, Yuan Wen, Shi Fu Chen, and Wen Fang on November 29, 2021 and is headquartered in Hong Kong. | Directeur/Membre du Conseil | 29/01/2023 |
Anciens postes connus de Li Ning Li
| Sociétés | Poste | Fin |
|---|---|---|
| Grains Valley Venture Capital | Directeur des opérations | 02/01/2009 |
Formation de Li Ning Li
| China Pharmaceutical University | Undergraduate Degree |
| University of Cardiff | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
HaploX Investment Holding Ltd.
HaploX Investment Holding Ltd. Miscellaneous Commercial ServicesCommercial Services HaploX Investment Holding Ltd. engages in the provision of genetic testing solutions with a focus on using molecular diagnostics technologies. It offers genetic testing results that enable full cycle health management for cancer and other patients as well as health screening and risk assessment for individuals, genetic testing of pathogenic microbes, and other pathogens, to research and development genetic testing primarily for biopharmaceutical companies and research institutes. The company was founded by Ming Yan Xu, Yuan Wen, Shi Fu Chen, and Wen Fang on November 29, 2021 and is headquartered in Hong Kong. | Commercial Services |
| Grains Valley Venture Capital |